TITLE:
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer

CONDITION:
Colorectal Cancer

INTERVENTION:
5-Fluorouracil

SUMMARY:

      This 2 arm study will compare the safety and efficacy of oral Xeloda, or 5-fluorouracil in
      combination with leucovorin, in patients who have undergone surgery for colon cancer.
      Patients will be randomized to receive either Xeloda 1250mg/m2 po bid on days 1-14 every 21
      days, or leucovorin 20mg/m2 iv + 5-fluorouracil 425mg/m2 iv daily from day 1 to day 5 every
      28 days. The anticipated time on study treatment is 3-12 months, and the target sample size
      is 500+ individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  adult patients 18-75 years of age;

          -  histologically confirmed colon cancer with potentially curative resection of the
             tumor within 8 weeks before study initiation.

        Exclusion Criteria:

          -  previous chemotherapy
      
